PPARδ agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic PPARδ agonist | Not a steroid or a selective androgen receptor modulator. |
| Common synonyms | Cardarine, GW501516, GW-501516, endurobol | Names vary by supplier and literature source. |
| Appearance | White to off-white powder | Consistent with many small-molecule research chemicals. |
| Solubility | Low in water; soluble in DMSO and ethanol | Often prepared in organic solvent for laboratory work. |
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid and energy metabolism. |
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
== Thermodynamics == At constant temperature and pressure, one must consider the Gibbs free energy, G, while at constant temperature and volume, one must consider the Helmholtz free energy, A, for the reaction; and at constant internal energy and volume, one must consider the entropy, S, for the reaction. The constant volume case is important in geochemistry and atmospheric chemistry where pressure variations are significant. Note that, if reactants and products were in standard state (completely pure), then there would be no reversibility and no equilibrium. Indeed, they would necessarily occupy disjoint volumes of space. The mixing of the products and reactants contributes a large entropy increase (known as entropy of mixing) to states containing equal mixture of products and reactants and gives rise to a distinctive minimum in the Gibbs energy as a function of the extent of reaction. The standard Gibbs energy change, together with the Gibbs energy of mixing, determine the equilibrium state. In this article only the constant pressure case is considered. The relation between the Gibbs free energy and the equilibrium constant can be found by considering chemical potentials. At constant temperature and pressure in the absence of an applied voltage, the Gibbs free energy, G, for the reaction depends only on the extent of reaction: ξ (Greek letter xi), and can only decrease according to the second law of thermodynamics. It means that the derivative of G with respect to ξ must be negative if the reaction happens; at the equilibrium this derivative is equal to zero.
=== Digestion === Amino acids that move beyond the terminal ileum in the body are less likely to be absorbed for use in protein synthesis. They may pass out of the body or become absorbed by bacteria, thus appearing to have been digested instead of being present in the feces. The PDCAAS takes no account of where the proteins have been digested. Similarly, amino acids that are lost due to antinutritional factors present in many foods are assumed to be digested according to the PDCAAS. This is linked with the earlier problem, as an antinutritional factor may prevent the rat's small intestines from absorbing the protein but do not deter the rat's gut bacteria from doing so. In addition, older rats show lower PDCAAS-estimated fecal digestibility compared to young rats when the protein source contains antinutritional factors. The report of 1989 did make use of existing per-amino-acid ileum digestibility values, but the requirement of pumping material out of the ileum was seen as too cumbersome. The fecal digestibility of the entire protein was adopted as a convenient approximation. It was found to be within 10% of the true amino-acid digestibility when applied to most protein sources with the notable exception of grain legumes. With beans, peas and lentils, the true digestibility of methionine, cystine and tryptophan can be much lower. In 2013, the FAO proposed changing to Digestible Indispensable Amino Acid Score, which uses per-amino-acid ileum digestibility.
== Example of preparing a series of standard solutions == Suppose the concentration of glutamine in an unknown sample needs to be measured. To do so, a series of standard solutions containing glutamine is prepared to create a calibration curve. A table summarizing a method for creating these solutions is shown below:
Sources: en.wikipedia.org
=== Fractional base units and referenced KMD plots === Kendrick mass defect plots created by using fractional base units exhibit enhanced resolution. Referenced Kendrick mass defect plots (KMD plots referenced to the terminal group and adduct composition) with fractional base units can be used to obtain an overview of copolymer composition.
During 1988, it became apparent to the Soviets that oil and gas subsidies, along with the cost of maintaining massive troops levels, represented a substantial economic drain. In addition, the security advantage of a buffer zone was recognized as irrelevant and the Soviets officially declared that they would no longer intervene in the affairs of satellite states in Central and Eastern Europe. George H. W. Bush and Gorbachev met at the Moscow Summit in May 1988 and the Governors Island Summit in December 1988. In 1989, Soviet forces withdrew from Afghanistan without achieving their objectives. Later that year, the Berlin Wall, the Inner German border and the Iron Curtain fell. On 3 December 1989, Gorbachev and Bush declared the Cold War over at the Malta Summit. In February 1990, Gorbachev agreed with the US-proposed Treaty on the Final Settlement with Respect to Germany and signed it on 12 September 1990, paving the way for the German reunification. When the Berlin Wall came down, Gorbachev's "Common European Home" concept began to take shape. The two former adversaries were partners in the Gulf War against Iraq (August 1990 – February 1991). During the final summit in Moscow in July 1991, Gorbachev and Bush signed the START I arms control treaty.
=== January === January 13, 2009: South Korea, Taiwan, Japan, United States Global shipping experiences a drop in trade, as exports from South Korea dropping an annualised 30%, with Taiwan and Japan experiencing a 42% and 27% drop respectively. Outgoing traffic in the United States dropped 18% from Long Beach and Los Angeles.
==== Progressive multiple sclerosis ==== In 2011, mitoxantrone was the first medication approved for secondary progressive MS. In this population, tentative evidence supports mitoxantrone moderately slowing the progression of the disease and decreasing rates of relapses over two years. In 2026, tolebrutinib, a BTK inhibitor, was approved for non-relapsing secondary MS in the EU. It reduces the activity of microglia, immune cells in the brain, as well as of B cells. New approved medications continue to emerge. In March 2017, the FDA approved ocrelizumab as a treatment for primary progressive MS in adults, the first drug to gain that approval. It is also used for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. According to a 2021 Cochrane review, ocrelizumab may reduce worsening of symptoms for primary progressive MS and probably increases unwanted effects but makes little or no difference to the number of serious unwanted effects. In 2019, siponimod and cladribine were approved in the United States for the treatment of secondary progressive multiple sclerosis (SPMS). Subsequently, ozanimod was approved in 2020, and ponesimod was approved in 2021, which were both approved for management of CIS, relapsing MS, and SPMS in the U.S., and RRMS in Europe. Ocrelizumab/hyaluronidase was approved for medical use in the United States in September 2024.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.
It binds to and activates PPARδ, a nuclear receptor that regulates genes related to fatty acid oxidation and energy use. This activation alters transcription in tissues such as skeletal muscle and liver. The full range of downstream effects in humans is not fully established.
No, cardarine is not known to occur naturally in plants, animals, or humans. It is a synthetic molecule produced for laboratory research. Products labeled as cardarine should therefore be treated as manufactured chemicals with variable purity.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.